Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes
JAMA2003Vol. 290(17), pp. 2292–2292
Citations Over TimeTop 1% of 2003 papers
Steven E. Nissen, Taro Tsunoda, E. Murat Tuzcu, Paul Schoenhagen, Christopher B. Cooper, Muhammad Yasin, Gregory M. Eaton, Michael A. Lauer, W. Scott Sheldon, Cindy L. Grines, Stephen W. Halpern, Tim Crowe, James C. Blankenship, Richard A. Kerensky
Abstract
A recombinant ApoA-I Milano/phospholipid complex (ETC-216) administered intravenously for 5 doses at weekly intervals produced significant regression of coronary atherosclerosis as measured by IVUS. Although promising, these results require confirmation in larger clinical trials with morbidity and mortality end points.
Related Papers
- → Intravascular ultrasound imaging of human coronary arteries in vivo. Analysis of tissue characterizations with comparison to in vitro histological specimens.(1991)599 cited
- → Comparison of Intravascular Ultrasound and Quantitative Coronary Angiography for the Assessment of Coronary Artery Disease Progression(2007)130 cited
- → Intravascular ultrasound characteristics of atheroma in angiographically “normal” segments(1991)6 cited
- → Emerging Role of Intravascular Ultrasound in the Assessment of Experimental Anti-Atherosclerotic Therapies(2006)4 cited
- Prediction of mechanical properties of human atherosclerotic tissue by high-frequency intravascular ultrasound imaging. An in vitro study.(1992)